Trial Profile
A Phase I, Single-Center, Double-Blind, Randomized, Placebo- and Positive- Controlled, Parallel Group, Thorough QT/QTc Study to Evaluate the Effect of Talampanel on Cardiac Repolarization in Healthy Male and Female Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Talampanel (Primary) ; Moxifloxacin
- Indications Amyotrophic lateral sclerosis; Bacterial infections; Drug-induced dyskinesia; Epilepsy; Glioma
- Focus Pharmacodynamics
- Sponsors Teva Pharmaceutical Industries
- 31 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Oct 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.